BACKGROUND The neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), as markers of systematic inflammation response, have been reported to be indicators in metastatic castration-resistant prostate cancer (mCRPC), whereas their prognostic values remain conflict. This study was to assess the prognostic value of NLR and PLR in mCRPC patients and to assess the response of abiraterone or enzalutamide through using NLR and PLR. METHODS Databases searching was conducted in the PubMed, EMBASE, Google Scholar, and the Cochrane Library for relevant published literature up to October 2019. Data extraction and quality evaluation were performed on the eligible studies. STATA 14.0 software was used to pooled hazard ratios (HRs) and their 95% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS). RESULTS A total of 3144 mCRPC patients were enrolled from 15 cohort studies in this meta-analysis. The pooled results demonstrated that elevated NLR had a significant association with inferior OS in mCRPC patients treated with abiraterone (HR = 1.63, 95% CI: 1.43-1.85, P < 0.001) and enzalutamide (HR = 1.48, 95% CI: 1.27-1.72, P < 0.001), whereas elevated NLR had no significant association with unfavorable PFS treated with abiraterone and enzalutamide, respectively. Elevated PLR had a significant association with an inferior OS (HR = 1.52, 95% CI: 1.16-1.98, P < 0.001) in mCRPC patients treated with abiraterone. CONCLUSIONS NLR and PLR were effective biomarkers for predicting prognosis in mCRPC patients and served as indicators of the efficacy of personalized treatment of mCRPC using abiraterone or enzalutamide. Future, more randomized control trials (RCTs) are needed to investigate the promising value of hematologic parameters.

中文翻译：

---

揭示阿比特龙或恩杂鲁胺治疗的转移性去势抵抗性前列腺癌患者中性粒细胞与淋巴细胞比率和血小板与淋巴细胞比率的预后情况：一项荟萃分析。

背景技术中性粒细胞与淋巴细胞之比（NLR）和血小板与淋巴细胞之比（PLR）作为系统性炎症反应的标志物已被报道是转移性去势抵抗性前列腺癌（mCRPC）的指标，而其预后价值观仍然存在冲突。本研究旨在评估NLR和PLR在mCRPC患者中的预后价值，并通过使用NLR和PLR评估阿比特龙或enzalutamide的反应。方法截至2019年10月，在PubMed，EMBASE，Google Scholar和Cochrane图书馆中进行数据库搜索，以获取相关发表的文献。对符合条件的研究进行了数据提取和质量评估。使用STATA 14.0软件汇总了危险比（HR）及其95％置信区间（CI），用于总体生存率（OS）和无进展生存期（PFS）。结果这项荟萃分析共纳入15项队列研究中的3144例mCRPC患者。汇总结果表明，在用阿比特龙（HR = 1.63，95％CI：1.43-1.85，P <0.001）和恩杂鲁胺（HR = 1.48，95％CI：1.27-）治疗的mCRPC患者中，NLR升高与OS降低密切相关。 1.72，P <0.001），而升高的NLR与分别使用阿比特龙和恩杂鲁胺治疗的不良PFS没有显着相关性。在阿比特龙治疗的mCRPC患者中，升高的PLR与下位OS显着相关（HR = 1.52，95％CI：1.16-1.98，P <0.001）。结论NLR和PLR是预测mCRPC患者预后的有效生物标志物，可作为使用阿比特龙或enzalutamide个性化治疗mCRPC疗效的指标。未来，